Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 22, Issue 21
1 November 2016
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows a section of a head and neck xenograft tumor in mice. Hematoxylin and eosin staining shows characteristic features of head and neck squamous cell carcinoma evident by hyperchromatism, pleomorphism, loss of polarity, and increased mitotic activity. For details, see the article by Yoo and colleagues on page 5265 of this issue.
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Martin Felices; Jeffrey S. Miller
View articletitled, Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Open the PDF for in another window
Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity
Carter M. Suryadevara; Katherine A. Riccione; John H. Sampson
View articletitled, Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity
Open the PDF for in another window

CCR Perspectives in Regulatory Science and Policy

Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study
Kun He; Huanyu Chen; Thomas Gwise; Sandra Casak; Steven Lemery; Patricia Keegan; Richard Pazdur; Rajeshwari Sridhara
View articletitled, Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study
Open the PDF for in another window

CCR Drug Updates

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
Erin Larkins; Gideon M. Blumenthal; Huanyu Chen; Kun He; Rajiv Agarwal; Gerlie Gieser; Olen Stephens; Eias Zahalka; Kimberly Ringgold; Whitney Helms; Stacy Shord; Jingyu Yu; Hong Zhao; Gina Davis; Amy E. McKee; Patricia Keegan; Richard Pazdur
View articletitled, FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
Open the PDF for in another window
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non–Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Ferdinandos Skoulidis; Vassiliki A. Papadimitrakopoulou
View articletitled, Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non–Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake; William C. Dougall; John J. Miles; Michele W.L. Teng; Mark J. Smyth
View articletitled, Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Open the PDF for in another window

Reviews

NAD+ Kinase as a Therapeutic Target in Cancer
Philip M. Tedeschi; Nitu Bansal; John E. Kerrigan; Emine E. Abali; Kathleen W. Scotto; Joseph R. Bertino
View articletitled, NAD<sup>+</sup> Kinase as a Therapeutic Target in Cancer
Open the PDF for in another window
Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response
Kerstin N. Timm; Brett W.C. Kennedy; Kevin M. Brindle
View articletitled, Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response
Open the PDF for in another window

Clinical Trial Brief Report

An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N. Khalil; Michael A. Postow; Nageatte Ibrahim; Dale L. Ludwig; Jan Cosaert; Siva Rama Prasad Kambhampati; Shande Tang; Dmitri Grebennik; John Sae Wook Kauh; Heinz-Josef Lenz; Keith T. Flaherty; F. Stephen Hodi; Donald P. Lawrence; Jedd D. Wolchok
View articletitled, An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Supplementary data
Open the PDF for in another window

Cancer Therapy: Clinical

Author Choice
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten; Neha Korde; Ritesh Kotecha; Robert Reger; Simona Bor; Dickran Kazandjian; Ola Landgren; Richard W. Childs
View articletitled, Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Supplementary data
Open the PDF for in another window
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
Xin Li; Yingying Cui; Zhenchang Sun; Lei Zhang; Ling Li; Xinhua Wang; Jingjing Wu; Xiaorui Fu; Wang Ma; Xudong Zhang; Yu Chang; Feifei Nan; Wencai Li; Liping Su; Jinghua Wang; Hongwei Xue; Mingzhi Zhang
View articletitled, DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
Open the PDF for in another window
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi; Raghvendra M. Srivastava; Fernando Concha-Benavente; Soldano Ferrone; Tatiana M. Garcia-Bates; Jing Li; Robert L. Ferris
View articletitled, Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Supplementary data
Open the PDF for in another window
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Katrien Berns; Amir Sonnenblick; Annemiek Gennissen; Sylvain Brohée; E. Marielle Hijmans; Bastiaan Evers; Debora Fumagalli; Christine Desmedt; Sibylle Loibl; Carsten Denkert; Patrick Neven; Wei Guo; Fan Zhang; Theo A. Knijnenburg; Tjalling Bosse; Michiel S. van der Heijden; Sanne Hindriksen; Wouter Nijkamp; Lodewyk F.A. Wessels; Heikki Joensuu; Gordon B. Mills; Roderick L. Beijersbergen; Christos Sotiriou; René Bernards
View articletitled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Supplementary data
Open the PDF for in another window

Personalized Medicine and Imaging

Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients
Judith S. Brand; Elham Hedayati; Keith Humphreys; Jonas F. Ludvigsson; Anna L.V. Johansson; Jonas Bergh; Per Hall; Kamila Czene
View articletitled, Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients
Supplementary data
Open the PDF for in another window
Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI
Ke Nie; Liming Shi; Qin Chen; Xi Hu; Salma K. Jabbour; Ning Yue; Tianye Niu; Xiaonan Sun
View articletitled, Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
Ji Young Yoo; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Hongsheng Dai; Tejaswini Nallanagulagari; Jeffrey Wojton; Brian S. Hurwitz; Theresa Relation; Tae Jin Lee; Michael T. Lotze; Jun-Ge Yu; Jianying Zhang; Carlo M. Croce; Jianhua Yu; Michael A. Caligiuri; Matthew Old; Balveen Kaur
View articletitled, Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy
Supplementary data
Open the PDF for in another window
Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Koji Munakata; Mamoru Uemura; Shinji Tanaka; Kenji Kawai; Tomohiro Kitahara; Masaaki Miyo; Yoshihiro Kano; Shinpei Nishikawa; Takahito Fukusumi; Yusuke Takahashi; Taishi Hata; Junichi Nishimura; Ichiro Takemasa; Tsunekazu Mizushima; Masakazu Ikenaga; Takeshi Kato; Kohei Murata; John M. Carethers; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
View articletitled, Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Supplementary data
Open the PDF for in another window
Author Choice
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
L. Tiffany Lyle; Paul R. Lockman; Chris E. Adkins; Afroz Shareef Mohammad; Emily Sechrest; Emily Hua; Diane Palmieri; David J. Liewehr; Seth M. Steinberg; Wojciech Kloc; Ewa Izycka-Swieszewska; Renata Duchnowska; Naema Nayyar; Priscilla K. Brastianos; Patricia S. Steeg; Brunilde Gril
View articletitled, Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
Supplementary data
Open the PDF for in another window
Ultrastructural Insights into the Biological Significance of Persisting DNA Damage Foci after Low Doses of Ionizing Radiation
Yvonne Lorat; Stefanie Schanz; Claudia E. Rübe
View articletitled, Ultrastructural Insights into the Biological Significance of Persisting DNA Damage Foci after Low Doses of Ionizing Radiation
Open the PDF for in another window
BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Aleksandra Olow; Sabine Mueller; Xiaodong Yang; Rintaro Hashizume; Justin Meyerowitz; William Weiss; Adam C. Resnick; Angela J. Waanders; Lukas J.A. Stalpers; Mitchel S. Berger; Nalin Gupta; C. David James; Claudia K. Petritsch; Daphne A. Haas-Kogan
View articletitled, BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Supplementary data
Open the PDF for in another window
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Paola Francica; Lluís Nisa; Daniel M. Aebersold; Rupert Langer; Friedhelm Bladt; Andree Blaukat; Deborah Stroka; María Rodríguez Martínez; Yitzhak Zimmer; Michaela Medová
View articletitled, Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Supplementary data
Open the PDF for in another window

Biology of Human Tumors

Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
Feng Geng; Xiang Cheng; Xiaoning Wu; Ji Young Yoo; Chunming Cheng; Jeffrey Yunhua Guo; Xiaokui Mo; Peng Ru; Brian Hurwitz; Sung-Hak Kim; Jose Otero; Vinay Puduvalli; Etienne Lefai; Jianjie Ma; Ichiro Nakano; Craig Horbinski; Balveen Kaur; Arnab Chakravarti; Deliang Guo
View articletitled, Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
Supplementary data
Open the PDF for in another window
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Hanwei Zhang; Kris Prado; Kelvin X. Zhang; Elizabeth M. Peek; Jane Lee; Xiaoyan Wang; Jiaoti Huang; Gang Li; Matteo Pellegrini; Arnold I. Chin
View articletitled, Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Supplementary data
Open the PDF for in another window
Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Rekha Gyanchandani; Yan Lin; Hui-Min Lin; Kristine Cooper; Daniel P. Normolle; Adam Brufsky; Michael Fastuca; Whitney Crosson; Steffi Oesterreich; Nancy E. Davidson; Rohit Bhargava; David J. Dabbs; Adrian V. Lee
View articletitled, Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Supplementary data
Open the PDF for in another window
PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation
De-Wei Wu; Tzu-Chin Wu; Chih-Yi Chen; Huei Lee
View articletitled, PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of <em>EGFR</em> Mutation
Supplementary data
Open the PDF for in another window
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Zhang Xiao Ying; Meiyan Jin; Luke F. Peterson; Denzil Bernard; Kamlai Saiya-Cork; Mehmet Yildiz; Shaomeng Wang; Mark S. Kaminski; Alfred E. Chang; Daniel J. Klionsky; Sami N. Malek
View articletitled, Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Supplementary data
Open the PDF for in another window

Advertisement

Breaking
GSK Buys Gastrointestinal-Focused Biopharma
Eli Lilly Snaps Up PI3Kα Inhibitor
$500,000 Purse Announced for TBXT Drugs
View more recent articles
Latest News
Greater Certainty of Survival Valued Over Speedier Drug Access
Keto Diet Key to Fueling CARs?
ADC for Lymphoma Elicits Near-Perfect Response Rate
View more recent articles
Research Watch
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
Engineered Focal Oncogene Amplifications Drive Transformation and Progression
Glycolysis Dictates Response to Fasting-Mimicking Diet in Breast Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept